October 2024 - ITPC MENA

9 October 2024

ViiV HEALTHCARE TO TRIPLE ANNUAL SUPPLY OF LONG-ACTING HIV PREP FOR LOW- AND MIDDLE-I…

Health Financing, Intellectual Property, Plaidoyer, VIH, الترافع 293 Views

Source : ITPC EECA Against the backdrop of a recent press release from Gilead announcing the signing of a voluntary license for the new drug lenacapavir, ViiV Healthcare has announced an increase in the

5 October 2024

“Not in Our Name” – African HIV Treatment Advocates React to Gilead’s Voluntary Licen…

Intellectual Property, Non classé, Plaidoyer, VIH, الترافع 1131 Views

Press Statement – 4 October 2024 Today’s announcement by Gilead that six generic manufacturers have been awarded voluntary licenses for the production of lenacapavir—a groundbreaking, twice-yearly injectable for HIV prevention and potential treatment—raises significant concerns

5 October 2024

Why the World Can’t Trust Pharmaceutical Companies to Ensure Global Access to Essenti…

Intellectual Property, Plaidoyer, VIH, الترافع 85 Views

Source : ITPC Global ITPC Global’s reaction to Gilead’s voluntary licence on lenacapravir: Gilead’s announcement of their voluntary license for lenacapavir—a groundbreaking, long-acting HIV prevention method—highlights why we cannot rely on pharmaceutical companies to